Synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
== E == Setsuro Ebashi (1922–2006). Japanese biochemist at the University of Tokyo who discovered troponin. Richard H. Ebright (b. 1959). American molecular biologist at Rutgers University, known for work on protein-DNA interaction, aspects of transcription, and antibacterial drug discovery. John Tileston Edsall (1902–2002). American protein chemist at Harvard, very influential in protein research, and author (with Edwin Cohn) of Proteins, Amino Acids and Peptides. Member Natl. Acad. Sci. USA. Konstantin Efetov (b. 1958). Ukrainian biochemist at Crimea State Medical University, known for work in molecular immunology, evolutionary biology, and biosystematics. Gertrude B. Elion (1918–1999). American biochemist and pharmacologist at Duke University, known for using rational drug design for the discovery of new drugs. Nobel Prize in Physiology or Medicine (1988). Conrad Elvehjem (1901–1962). American biochemist and nutritionist at the University of Wisconsin, known for identifying two vitamins, nicotinic acid, and nicotinamide. Gladys Anderson Emerson (1903–1984). American historian, biochemist and nutritionist at UCLA, the first to isolate Vitamin E in a pure form. Akira Endo (1933–2024). Japanese biochemist at the Tokyo University of Agriculture and Technology. His research into the relationship between fungi and cholesterol biosynthesis led to the development of statin drugs. Foreign associate Natl. Acad. Sci. USA. Donald Engelman (b. 1941). American biochemist at Yale, involved in the creation of new cancer drugs and treatments. Member Natl. Acad. Sci.
A morgen ("morning" in Dutch and German) was approximately the amount of land tillable by one man behind an ox in the morning hours of a day. This was an official unit of measurement in South Africa until the 1970s, and was defined in November 2007 by the South African Law Society as having a conversion factor of 1 morgen = 0.856532 hectares. This unit of measure was also used in the Dutch colonial province of New Netherland (later New York and parts of New England).
== Global occurrence and sources == PFOA contaminates every continent. Two of the most common types of PFAS (more precisely, PFOS and PFOA) were phased out of production in the United States (US) in 2002 and 2015 respectively, but are still present in some imported products. PFOA and PFOS are found in every American person's blood stream in the parts per billion range, though those concentrations have decreased by 70% for PFOA and 84% for PFOS between 1999 and 2014, which coincides with the end of the production and phase out of PFOA and PFOS in the US. PFOA has been detected in the central Pacific Ocean at low parts per quadrillion ranges, and at low parts per trillion (ppt) levels in coastal waters. Due to the surfactant nature of PFOA, it has been found to concentrate in the top layers of ocean water. PFOA is detected widely in surface waters, and is present in numerous mammals, fish, and bird species. PFOA is in the blood or vital organs of Atlantic salmon, swordfish, striped mullet, gray seals, common cormorants, Alaskan polar bears, brown pelicans, sea turtles, sea eagles, Midwestern bald eagles, California sea lions and Laysan albatrosses on Sand Island, a wildlife refuge on Midway Atoll, in the middle of the North Pacific Ocean, about halfway between North America and Asia. Because PFAS are ubiquitous in households, consumer products, food, and the environment generally, some trace levels reflecting this ubiquitous broad use of these compounds will make their way into the wastewater and solid waste streams.
Sources: en.wikipedia.org
=== No development reported === Guanfacine extended release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist [23] Riluzole sublingual (BHV-0223; Nurtec) – various actions [24] Sertraline (Aremis; Besitran; CP-51974; Gladem; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) [25]
== Background == Enzymes are proteins that catalyze (i.e. accelerate) chemical reactions. They are natural catalysts and are ubiquitous, in plants, animals and microorganisms where they catalyze processes that are vital to living organisms. They are intimately involved in numerous biotechnological processes, such as cheese making, beer brewing and winemaking, that date back to the dawn of civilization. Recent advances in biotechnology, particularly in genetic and protein engineering, and genetics have provided the basis for the efficient development of enzymes with improved properties for established applications and novel, tailor-made enzymes for completely new applications where enzymes were not previously used. Today, enzymes are widely applied in many different industries and the number of applications continues to increase. Examples include food (baking, dairy products, starch conversion) and beverage (beer, wine, fruit and vegetable juices) processing, animal feed, textiles, pulp and paper, detergents, biosensors, cosmetics, health care and nutrition, waste water treatment, pharmaceutical and chemical manufacture and, more recently, biofuels such as biodiesel. The main driver for the widespread application of enzymes is their small environmental footprint. Many traditional chemical conversions used in various industries suffer from inherent drawbacks from both an economic and environmental viewpoint. Non-specific reactions can afford low product yields, copious amounts of waste and impure products.
An individual with a transsexual or gender dysphoria diagnosis can, together with the assessment team and other doctors, decide what suits them. Medically transitioning in Sweden is covered by the high-cost protection for medications and doctor's visits, and there is no surgery fee. The fee the individual pays for a doctor's appointment or other care represents only a small fraction of the actual costs. If a person would like to change their legal gender marker and personal identity number they will have to seek permission from the National Board of Health and Welfare. For non-binary persons younger than 18 years, the healthcare is limited. These individuals do not have access to a legal gender marker change or bottom surgery. In Sweden, anyone is allowed to change their name at any time, including for gender transition. Up until January 27, 2017, being transsexual was classed as a disease. Two months earlier, on November 21, 2016, around 50 trans activists broke into and occupied the Swedish National Board of Health and Welfare (Swedish: Socialstyrelsen) premises in Rålambsvägen in Stockholm. The activists demanded that their voices be heard regarding the way the country, healthcare, and the National Board of Health and Welfare mistreat transgender and intersex individuals. Sweden's Karolinska Institute, administrator of the second-largest hospital system in the country, announced in March 2021 that it would discontinue providing puberty blockers or cross-sex hormones to children under 16.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.